Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
This technology was licensed from Dr. Tejal Desai’s lab where Crystal Nyitray, co-founder and CEO, worked on the discovery as a grad student.